A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

• Status: Terminated
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to compare their tolerability and efficacy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Risperidone; Ziprasidone

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia

• CGI-S score of 4 or less at baseline

Exclusion Criteria:

• Concurrent antipsychotic treatment

• Treatment with antidepressants or mood stabilizers within 2 weeks of randomization

• Acute exacerbation of schizophrenia within 3 months of baseline